Welcome to our dedicated page for Halberd news (Ticker: HALB), a resource for investors and traders seeking the latest updates and insights on Halberd stock.
Halberd Corporation reports developments in medical research programs focused on traumatic brain injury, PTSD, suicide ideation, dialysis-borne neuropathy and pruritus. The company’s updates describe its proprietary nasal spray approach for post-head-trauma treatment, its LDX compound, and work with Athena GTX, Athena Telemedicine Partners and scientists at Mississippi State University.
Recurring news also covers Halberd’s NeuroSense AI acquisition and behavioral intelligence platform, which combines multi-modal behavioral data with artificial intelligence for TBI research and clinical assessment. Other company updates address patent-related assets, government-contract efforts, private funding discussions, and OTC public-company communications.
Halberd Corporation has reported the successful application of its patented methodology for Cancer Antigen Eradication Treatment. CEO William Hartman and CTO Mitchell Felder discussed these groundbreaking achievements in an interview. The company's approach involves controlling cancer antigen levels, specifically CTLA-4, to enhance immune response without harmful side effects. This extracorporeal method aims to minimize drug-related fatalities, with over 100,000 deaths annually in the U.S. attributed to medication side effects. Halberd is progressing from in-vitro to in-vivo testing, seeking to advance its innovative treatment.
Summary not available.
Halberd Corporation (OTC PINK:HALB) announced a peer-reviewed scientific article demonstrating its novel monoclonal antibody, which significantly boosts the effectiveness of an existing Covid antibody cocktail against the Omicron variant from 65% to over 94%. This achievement underscores the company’s innovative research capabilities. Halberd's antibody showcased effectiveness against all Covid-19 strains tested, indicating its potential for broad application in treating Covid-19. The article is set to be published soon, highlighting Halberd's ongoing commitment to advancing Covid-19 therapies.
Halberd Corporation has achieved significant success in laboratory tests, eradicating five key cancer disease antigens, including CTLA-4, using a patented process with laser emissive energy in under ten minutes. This innovative method aims to eliminate cancer-causing antigens from bodily fluids, potentially offering safer treatments with fewer side effects compared to conventional therapies. The company plans to target the BTLA antigen shortly. Halberd also emphasizes its commitment to reducing treatment costs and improving effectiveness through precise control of cancer antigens.
Halberd Corporation (OTC-PINK:HALB) has partnered with the newly formed Hamden Group, led by Darren Hamans and the Croden family, to enhance sales and distribution of its patented low-dose Naltrexone medication and Vita-Shield-Max™ nutraceutical product. The Hamden Group possesses extensive pharmaceutical experience, aiming to accelerate revenue for HALB. This contract grants Hamden exclusive rights worldwide for sales and marketing. CEO William Hartman notes the significant potential in sales for these products targeting various health conditions, including MS and addiction.
Halberd Corporation (OTC PINK:HALB) executives William A. Hartman and Dr. Mitchell S. Felder discussed transformative research milestones and their implications for healthcare during an interview on The Street Reports. They emphasized how their innovations could significantly impact the treatment of various diseases. Halberd, since its restructuring in 2020, has secured exclusive rights to three patents and has filed 22 additional patent applications to enhance stockholder value and attract development partners. For further updates, interested individuals can subscribe via the company's contact page.
Halberd Corporation (OTC PINK:HALB) announced the successful elimination of various antibiotic-resistant bacteria using a unique monoclonal antibody combined with a metallic nanoparticle. This method reportedly kills over 90% of bacteria in less than 20 minutes, a significant improvement over traditional antibiotics that can take up to 10 days. The technology targets Gram-negative bacteria, including E. coli and Salmonella, and the CDC will provide antibiotic-resistant samples for further research. Halberd believes this breakthrough could revolutionize treatment for sepsis and other serious infections.
Halberd Corporation (OTC PINK:HALB) has successfully removed Interleukin-6 (IL-6) from human blood serum in recent laboratory tests. IL-6 is linked to inflammation and diseases like rheumatoid arthritis and certain cancers. Unlike previous methods using laser irradiation on cerebrospinal fluid, this new approach employs a specially engineered antibody bonded to a microbead filter. The CEO highlighted the platform's potential for universal application in treating various diseases. The company has also secured exclusive rights to three patents, enhancing its value for shareholders.
Halberd Corporation (OTC PINK:HALB) announced a strategic alliance with AI Longevity, Inc. and Stem of Hope to create a subsidiary named Extendalife focused on longevity and treatments for Alzheimer's Disease and Cancer. The alliance aims to leverage patented technologies for disease treatment and longevity enhancement.
The team plans to start animal testing by year-end, with expectations for initial feasibility results in improving longevity. Halberd intends to spin off Extendalife as a publicly traded entity, granting shares to current shareholders, enhancing potential shareholder value.
Halberd Corporation (OTC PINK:HALB) has successfully demonstrated the ability to control PD-1 levels in human blood serum during lab tests. This process, which can effectively eliminate PD-1, could empower the body's immune system to target cancer tumors more effectively. The company’s patented technique offers a swift restoration of PD-1 levels, potentially revolutionizing cancer immunotherapy. Both Dr. Mitchell S. Felder and CEO William A. Hartman expressed optimism regarding the implications of these results for safer and more effective cancer treatments.